Enterologics Inc. (fka ELGO)

[stockforyou1]

$ELGO.ob $0.48 - Business Summary

Enterologics, Inc., a biopharmaceutical company, intends to develop, market, and commercialize probiotic biotherapeutic drug products. It focuses on developing treatments for gastrointestinal disorders, such as pouchitis, irritable bowel syndrome, Crohn?s disease, ulcerative colitis, and Clostridium difficile infections. The company was founded in 2009 and is based in Cedarhurst, New York.

$ELGO PR on April 18th - Enterologics, Inc. to Develop Probiotics as Biologic Drugs for Gastrointestinal Diseases
Enterologics, Inc. Announces Its Business Strategy to Develop a Pipeline of Specific Probiotic Strains as Biologic Drugs for Gastrointestinal Disease Conditions
http://finance.yahoo.com/news/Enterologics-Inc-to-Develop-iw-1468871040.html?x=0&.v=1

$ELGO PR on April 26th - Enterologics, Inc. Launches Corporate Website www.enterologics.com
http://finance.yahoo.com/news/Enterologics-Inc-Launches-iw-3283438027.html?x=0&.v=1

$ELGO PR on January 11th - Enterologics and Universal Stabilization Technologies (UST) to jointly evaluate new stabilization technology for probiotics
http://www.sec.gov/Archives/edgar/data/1483731/000121390011000149/f8k011211_enterologics.htm

Who we are:
Enterologics is a publicly traded company (ELGO.OB). We were founded in 2009 for the sole purpose of making probiotics available as new therapeutic alternatives for inadequately treated GI diseases. We operate as a virtual team of experts and partner with the best outside biologic production resources we can identify. Our goal is to keep development costs low and make time to market as fast as possible.

Our mission is to bring unique strains of probiotic bacteria to market as FDA-approved “live biotherapeutics” for gastrointestinal diseases.

Our guiding principles:
Minimize development risk. Probiotic strains we acquire will have prior human use and evidence of safety and therapeutic benefits. We will build a strong scientific portfolio by extensive strain characterization, including state-of-the-art genomic profiling.

Enhance value by following a rigorous product development template. We develop our probiotic strains as “live biotherapeutics” following FDA guidelines to demonstrate the safety and clinical efficacy of biologic drugs. This builds the scientific underpinnings needed to ensure the highest quality product and unequivocal demonstration of clinical benefit.

Engineer quality and product performance. Selection of the optimal dosage form is important as the right probiotic. We have identified a superior formulation technology called “vitrification” that extends shelf live better than traditional freeze-drying. This new preservation technology, coupled with rigorous production and quality standards, will ensure prescriber confidence that our products deliver viable bacteria at a reproducible and effective dose.